Lilly, Boehringer diabetes drug reduces cardiovascular risk in trial

FRANKFURT, Aug 20 (Reuters) - A clinical trial showed that diabetes drug Jardiance, co-promoted by Eli Lilly and Boehringer Ingelheim, reduces cardiovascular risk in patients with type 2 diabetes, Boehringer Ingelheim said in a statement on Thursday.